Greater List Price Transparency Will Help Hold Big Pharma Accountable, Deter Price-Gouging
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today encouraging the U.S. House Committee on Energy & Commerce to advance the FAIR Drug Pricing Act being considered in a markup of over two dozen bills by the full panel on Wednesday.
“Greater list price transparency is critical to shining a light on Big Pharma’s price-gouging and helping to deter the industry’s egregious pricing practices,” said CSRxP executive director Lauren Aronson. “The FAIR Drug Pricing Act will compel drug makers to justify excessive list price hikes and is an important market-based solution to hold Big Pharma accountable.”
“We applaud Chairman Pallone, Ranking Member Walden, Rep. Schakowsky and Rep. Rooney for their bipartisan collaboration to increase prescription drug transparency,” Aronson continued. “We encourage Energy and Commerce lawmakers to help deliver for American patients by advancing the FAIR Drug Pricing Act in bipartisan fashion Wednesday.”
The FAIR Drug Pricing Act was introduced in the U.S. House by Reps. Jan Schakowsky (D-IL) and Francis Rooney (R-FL).
A U.S. Senate companion of the bill, sponsored by Sens. Tammy Baldwin (D-WI) and Mike Braun (R-ID), was added to a healthcare package that passed out of the Senate Committee on Healthcare, Education, Labor and Pensions (HELP) on June 26.